|
US8541008B2
(en)
*
|
1999-11-19 |
2013-09-24 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Pharmaceutical compositions and methods to vaccinate against candidiasis
|
|
US20070077256A1
(en)
|
1999-11-19 |
2007-04-05 |
Los Angeles Biomedical Research Institute |
Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
CN1487996B
(zh)
*
|
2000-11-30 |
2010-06-16 |
米德列斯公司 |
用于生产人类抗体的转基因转染色体啮齿动物
|
|
US7476536B2
(en)
*
|
2001-05-11 |
2009-01-13 |
Kirin Pharma Kabushiki Kaisha |
Artificial human chromosome containing human antibody a light chain gene
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
ES2408582T3
(es)
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Biblioteca de Fab para la preparación de una mezcla de anticuerpos
|
|
CN102558352A
(zh)
|
2003-06-27 |
2012-07-11 |
艾默根佛蒙特有限公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
|
WO2005092926A2
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
|
NZ554824A
(en)
*
|
2004-10-22 |
2010-10-29 |
Revivicor Inc |
Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
|
|
US20080026457A1
(en)
|
2004-10-22 |
2008-01-31 |
Kevin Wells |
Ungulates with genetically modified immune systems
|
|
EP1851245B1
(en)
|
2005-01-26 |
2012-10-10 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
|
MX2007013058A
(es)
|
2005-04-20 |
2008-02-22 |
Amgen Fremont Inc |
Anticuerpos monoclonales de alta afinidad completamente humanos para interleucina-8 y epitopes para dichos anticuerpos.
|
|
JP2008538912A
(ja)
*
|
2005-04-29 |
2008-11-13 |
イナート・ファルマ |
遺伝子導入動物および組換え抗体の製造方法
|
|
NL1029605C2
(nl)
*
|
2005-07-25 |
2007-01-26 |
Li-Te Chin |
Nieuwe uit menselijke kiemlijnsequenties gewonnen antilichaamstructuren.
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
AU2008255350B2
(en)
|
2007-05-31 |
2014-07-10 |
Genmab A/S |
Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
|
|
DK2602323T3
(en)
*
|
2007-06-01 |
2018-04-16 |
Open Monoclonal Tech Inc |
Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
|
|
EP2346994B1
(en)
|
2008-09-30 |
2022-02-16 |
Ablexis, LLC |
Knock-in mice for the production of chimeric antibodies
|
|
EP2348827B1
(en)
*
|
2008-10-27 |
2015-07-01 |
Revivicor, Inc. |
Immunocompromised ungulates
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
BR112012000536A2
(pt)
|
2009-07-08 |
2020-08-11 |
Kymab Limited |
métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
|
|
MX358013B
(es)
|
2009-11-13 |
2018-08-01 |
Amgen Inc |
Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
|
|
SI2501817T2
(sl)
|
2010-02-08 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Miš z navadno lahko verigo
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
KR102203727B1
(ko)
|
2010-03-31 |
2021-01-18 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
|
US9012717B2
(en)
|
2010-06-22 |
2015-04-21 |
Regeneron Pharmaceuticals, Inc. |
Human lambda light chain mice
|
|
SG10201912639SA
(en)
*
|
2010-08-02 |
2020-02-27 |
Regeneron Pharma |
Mice that make binding proteins comprising vl domains
|
|
AU2011286407A1
(en)
|
2010-08-06 |
2013-02-21 |
Amgen |
Use of HER3 binding agents in prostate treatment
|
|
JP6066912B2
(ja)
|
2010-10-27 |
2017-01-25 |
アムジエン・インコーポレーテツド |
Ｄｋｋ１抗体およびその使用方法
|
|
EP2704743B1
(en)
|
2011-05-04 |
2020-03-11 |
Omeros Corporation |
Compositions for inhibiting masp-2 dependent complement acitivation
|
|
CN103998056B
(zh)
|
2011-07-22 |
2017-09-12 |
诺瓦蒂格姆疗法有限公司 |
用于接种抗金黄色葡萄球菌疫苗的方法和组合物
|
|
RS59728B1
(sr)
|
2011-08-05 |
2020-02-28 |
Regeneron Pharma |
Humanizovani miševi univerzalnog lakog lanca
|
|
BR112014006394A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
|
|
WO2013041845A2
(en)
*
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Animals, repertoires & methods
|
|
EP2759551B1
(en)
|
2011-09-21 |
2019-05-22 |
Fujirebio Inc. |
Antibodies binding to an affinity complex comprising 25oh vitamin d2 or d3 and an antibody thereto
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
HK1202252A1
(en)
|
2011-11-16 |
2015-09-25 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
RU2664181C2
(ru)
|
2011-12-20 |
2018-08-15 |
Регенерон Фармасьютикалз, Инк. |
Мыши с гуманизированной легкой цепью
|
|
MX2014011047A
(es)
|
2012-03-16 |
2015-04-08 |
Regeneron Pharma |
Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph.
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
KR102228296B1
(ko)
|
2012-03-16 |
2021-03-17 |
리제너론 파마슈티칼스 인코포레이티드 |
히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
|
|
SG10201700360VA
(en)
|
2012-03-16 |
2017-03-30 |
Regeneron Pharma |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
JP5976380B2
(ja)
*
|
2012-04-27 |
2016-08-23 |
公益財団法人東京都医学総合研究所 |
ウロキナーゼ型プラスミノーゲンアクチベータートランスジェニックマウス
|
|
PT3597037T
(pt)
*
|
2012-06-12 |
2021-06-01 |
Regeneron Pharma |
Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
|
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
EP2840892B1
(en)
*
|
2013-02-20 |
2018-04-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
WO2014140358A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Single chain binding molecules comprising n-terminal abp
|
|
EP2968497B1
(en)
|
2013-03-15 |
2020-08-12 |
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center |
Compositions and methods for treating fungal and bacterial pathogens
|
|
WO2014140368A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza m2 and cd3
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
DE112014004537T5
(de)
|
2013-10-01 |
2016-07-21 |
Kymab Limited |
Tiermodelle und therapeutische Moleküle
|
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
KR102276752B1
(ko)
|
2014-03-21 |
2021-07-13 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
|
ES2743809T3
(es)
|
2014-07-31 |
2020-02-20 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
|
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
AU2015295242B2
(en)
|
2014-07-31 |
2020-10-22 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
ES2945313T3
(es)
|
2015-04-17 |
2023-06-30 |
Amgen Res Munich Gmbh |
Construcciones de anticuerpos biespecificos para CDH3 y CD3
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
CN116063544A
(zh)
|
2016-02-03 |
2023-05-05 |
安进研发（慕尼黑）股份有限公司 |
Bcma和cd3双特异性t细胞接合抗体构建体
|
|
EP3411404B1
(en)
|
2016-02-03 |
2022-11-09 |
Amgen Research (Munich) GmbH |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
US10857216B2
(en)
|
2016-03-09 |
2020-12-08 |
Novadigm Therapeutics, Inc. |
Methods and kits for use in preventing and treating vulvovaginal candidiasis
|
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
|
WO2017214089A1
(en)
|
2016-06-06 |
2017-12-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing antibodies with human lambda light chains
|
|
WO2018128691A1
(en)
|
2016-11-04 |
2018-07-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having an engineered immunoglobulin lambda light chain locus
|
|
NZ755816A
(en)
|
2017-01-19 |
2026-03-27 |
Omniab Inc |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
TN2019000225A1
(en)
|
2017-02-02 |
2021-01-07 |
Amgen Res Munich Gmbh |
Low ph pharmaceutical composition comprising t cell engaging antibody constructs
|
|
MX2019013142A
(es)
|
2017-05-05 |
2019-12-16 |
Amgen Inc |
Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
|
|
DK4140297T3
(da)
|
2017-12-05 |
2025-06-23 |
Regeneron Pharma |
Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf
|
|
KR20250111232A
(ko)
|
2017-12-11 |
2025-07-22 |
암젠 인크 |
이중특이적 항체 생성물의 연속 제조 공정
|
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
|
WO2020025532A1
(en)
|
2018-07-30 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
|
JOP20210022A1
(ar)
|
2018-08-03 |
2021-01-28 |
Amgen Inc |
بنيات جسم مضاد لـ cldn18.2وcd3
|
|
PT3843757T
(pt)
|
2018-08-27 |
2024-07-08 |
Affimed Gmbh |
Células nk criopreservadas pré-carregadas com uma construção de anticorpo
|
|
GB2576914A
(en)
*
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
|
SG11202111258TA
(en)
|
2019-06-05 |
2021-11-29 |
Regeneron Pharma |
Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
|
|
MX2021014644A
(es)
|
2019-06-13 |
2022-04-06 |
Amgen Inc |
Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
|
|
AU2020345787A1
(en)
|
2019-09-10 |
2022-03-24 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
|
|
AU2020381536A1
(en)
|
2019-11-13 |
2022-04-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
|
MX2022007688A
(es)
|
2019-12-20 |
2022-07-19 |
Amgen Inc |
Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
|
|
KR20220119467A
(ko)
|
2019-12-27 |
2022-08-29 |
아피메트 게엠베하 |
이중특이적 fcyriii x cd30 항체 작제물의 제조 방법
|
|
EP4093771A1
(en)
|
2020-01-22 |
2022-11-30 |
Amgen Research (Munich) GmbH |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
|
WO2021183861A1
(en)
|
2020-03-12 |
2021-09-16 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
|
|
KR20220155338A
(ko)
|
2020-03-19 |
2022-11-22 |
암젠 인크 |
뮤신 17에 대한 항체 및 이의 용도
|
|
US12312412B2
(en)
|
2020-05-19 |
2025-05-27 |
Amgen Inc. |
MAGEB2 binding constructs
|
|
AU2021281554A1
(en)
|
2020-05-29 |
2022-12-15 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific antibody construct binding to CD33 and CD3
|
|
JP2023545099A
(ja)
|
2020-10-08 |
2023-10-26 |
アフィメド ゲーエムベーハー |
三重特異性バインダー
|
|
EP4240767A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
|
AU2021374036A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs selectively binding to cldn6 and cd3
|
|
CN116323671A
(zh)
|
2020-11-06 |
2023-06-23 |
安进公司 |
具有增加的选择性的多靶向性双特异性抗原结合分子
|
|
IL301926A
(en)
|
2020-11-06 |
2023-06-01 |
Amgen Inc |
Antigen binding domain with reduced clipping rate
|
|
EP4263599A1
(en)
|
2020-12-16 |
2023-10-25 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
MX2023011690A
(es)
|
2021-04-02 |
2023-12-15 |
Amgen Inc |
Construcciones de unión a mageb2.
|
|
CN117279947A
(zh)
|
2021-05-06 |
2023-12-22 |
安进研发（慕尼黑）股份有限公司 |
用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
|
|
CA3216098A1
(en)
|
2021-07-30 |
2023-02-02 |
Uwe Reusch |
Duplexbodies
|
|
AU2022382368A1
(en)
|
2021-11-03 |
2024-05-02 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
JP2024543828A
(ja)
|
2021-11-03 |
2024-11-26 |
アフィメド ゲーエムベーハー |
二重特異性ｃｄ１６ａバインダー
|
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
EP4543473A1
(en)
|
2022-06-22 |
2025-04-30 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
US20260083841A1
(en)
|
2022-09-14 |
2026-03-26 |
Amgen Inc. |
Bispecific Molecule Stabilizing Composition
|
|
MX2025014635A
(es)
|
2023-06-14 |
2026-02-03 |
Amgen Inc |
Moleculas captadoras de enmascaramiento de celulas t
|